The Food and Drug Administration (FDA) has given the green light to Bayer to import foreign-labeled iopromide (Ultravist) to help alleviate ongoing supply challenges with iodinated contrast media in the United States.
In light of continued supply issues with iodinated contrast media stemming from a temporary COVID-19-related shutdown of a GE Healthcare manufacturing plant in Shanghai earlier this year, the Food and Drug Adminstration (FDA) is allowing Bayer to import and distribute foreign-labeled iopromide (Ultravist) in the United States.
Bayer emphasized that Ultravist is indicated for intra-arterial and intravenous administration. The modality is contraindicated for intrathecal administration, according to Bayer.
The company added that clinicians should be aware of differences between the package inserts for the foreign-labeled iopromide and the U.S. version, and defer to the U.S. prescribing information for iopromide.
For additional questions about the use of iopromide, one may contact Bayer Healthcare Pharmaceuticals at (888) 842-2937.
(Editor’s note: For related content, see “Iodinated Contrast Media Shortage: Practical Solutions and Applications in Radiology,” “Lessons Learned from the Iodinated Contrast Media Shortage: A Neuroradiologist’s Perspective,” “Emerging Strategies for Managing the Acute Shortage of Iodinated Contrast Media” and “Iodinated Contrast Media: 15 Recommendations for Addressing the Shortage.”)
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
Can a CT-Based Radiomics Model Bolster Detection of Malignant Thyroid Nodules?
May 3rd 2024A computed tomography (CT)-based radiomics model that includes 28 radiomic features showed significantly higher accuracy, sensitivity, and specificity than conventional CT in differentiating benign and malignant thyroid nodules, according to newly published research.